Facebook
Twitter
LinkedIn
WhatsApp

Stage 4 Cancer

Stage 4, Stage IV metastatic cancer

“Metastases cancer” or stage 4 cancer, is the medical term for describing a condition where a tumor originating in a certain organ, “primary tumor”, is identified in another organ or in a distant location from the original organ, e.g., metastases of breast cancer can be found in the lungs, brain, bones and liver.

It is important to note, metastases are the same type of the original primary tumor, even if its location is in distant organs and so are the treatments regarded as such, for example, a treatment for a metastatic lung cancer that has spread to the liver, is determined by the treatment for metastatic lung cancer and not by the treatment for liver cancer.

Metastases formation

Cancer cells of the primary tumor can be released into the bloodstream and lymphatic system and circulate to distant organs or adjacent organs and tissues to the primary tumor and “settle” in them and grow.

There are different types of cancer which is known where metastases can be formed, for example,

  • Breast cancer can spread to the bones, brain, liver and lungs
  • Lung cancer can spread to the brain, bones, liver and kidney
  • Prostate cancer can spread to the bones
  • Colon cancer, rectal cancer, colorectal cancer can spread to the liver and lungs
Breast cancer can spread to the bones, brain, liver and lungs
Breast cancer can spread to the bones, brain, liver and lungs

Stage IV metastatic cancer and recovery

In the vast majority of the metastatic cases, the treatments do not cure. Treatment goals are slowing tumor growth rate, prolonging life and reducing the symptoms of the disease, improving the quality of life of the patient.

The efficacy of the treatments is affected by many factors, among them are the type of cancer, number of metastases (also called “lesions”) and their location, how much cancer the patient has in his or her body, growth rate of the tumor lesions, medical history of the patient, background diseases, microenvironment between the tumor cells themselves, resistance the tumor has developed to previous treatments and other.

Advanced treatments and clinical trials for stage 4

The National Cancer Institute (NCI) highlights the fact that for a certain group of metastatic cancer patients, the best treatment option is to join one of the many clinical trials existing worldwide aiming to increase their chances of therapeutic success.

This is also recommended by the USA national comprehensive cancer network, NCCN,  (USA national comprehensive cancer network)

“Patients with cancer should be encouraged to participate in clinical trials during all aspects of their diagnosis and treatment”

Currently, every patient will be offered the standard protocols described above. Sometimes the oncologist may suggest integrating these therapies with trials carried out in the Institute.

Advances in cancer therapies may be found in clinical trials prescribing cutting edge, interesting drugs, some of which have already been recognized by the FDA (US Food & Drug Administration) as “breakthrough treatments” and require further information input before being finally and fully approved.

An entire world of clinical trials and compassionate drugs and treatments are open and available worldwide. It is important to know which cutting edge treatments exist which patients can gain far more from them than the standard care offered.

For most patients with stage 4 metastatic cancer, current treatments are insufficiently effective. This gives rise to the need for innovative strategies with greater efficacy in fighting the disease.

Read our publications on innovative treatments for stage 4 metastatic cancer:

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics

Facebook
Twitter
LinkedIn
WhatsApp

New hope for ovarian cancer patients – regardless of BRCA status

Background –

The first standard treatment for advanced ovarian cancer patients is platinum-based chemotherapy. If the patient responds to this chemotherapy, she will continue to receive it to the maximum that can be given because of cumulative toxicity in the body and not until the disease worsens. This means that an advanced ovarian cancer patient can receive treatment, respond to it, and then discontinue it. The patient is then enters a period of follow-up only where she does not receive treatment and usually ends when the disease progresses. This period is called “maintenance phase”.

A drug called “Niraprib”, commercial name “Zejula®”, was approved for the treatment of cancer patients with ovarian cancer whose tumor expresses a BRCA mutation and are BRCA carriers. This group of patients accounts for only about 15% of all ovarian cancer patients and the standard maintenance treatment in the remaining 85% of patients is “no treatment”.

Niraparib is taken orally once a day and belongs to the “PARP inhibitor” family.

About PRIMA study –

PRIMA is Phase 3 study designed to evaluate niraparib versus placebo in first-line platinum responsive Stage III or IV ovarian cancer patients without filtering by BRCA status. The study assesses the efficacy of niraparib as maintenance treatment, as measured by the length of time until the disease progresses, also called PFS and compared it with the group of patients who received placebo.

The results have been announced and are positive, demonstrating significant improvements in the length of time until the disease progresses (PFS) regardless of their BRCA status. The detailed results will be published in a near oncology meeting.

In addition to these findings the results for the safety and tolerability of Zejula was consistent with previous clinical trials.

There is no doubt that the patients who participated in the study earned the opportunity to gain treatment during the maintenance stage with the most advanced biological drug in the world. This treatment worked, was successful and they received it long before the drug will officially be approved by the world health authorities and reimbursed.

The best management for any patient with cancer is receiving the most innovative cancer drugs in advanced stages of development. There, the hope and chances to live longer go far beyond the standard protocols.

TRIAL•IN Pharma

Do not give up on life!

Contact us 24/7 for free service matching:

Call center +44.2082.426.039

www.trial-in.com

 

For further reading

No Cost service compatibility check
Please fill in the details and we will back to you as soon as possible

Improving therapeutic success, extending life and quality of life are our main business. We extend to metastatic cancer patients and patients with brain tumors, the most advanced treatment options in the world and the best experts in Israel and abroad.

Article categories

קטגוריות המאמרים

Popular topics